Accordingly, this sensitisation was also described for the combination of irinotecan and trabectedin with ATR inhibitor in PDX models.18,19 Whether low or absent SLFN11 cancers may be re-sensitised to chemotherapy with combinations of other DDRi, particularly those that also modulate the replication stress response, is currently unknown as an in-depth analysis of whether SLFN11 is associated with response to DDRi monotherapies other than PARPi. The gene discussed is SLFN11; the disease is cancer.